Levothyroxine

Dosage Form Proportions: 50 mg, 100 mg, and 200 mg Tablets in Fasted State

Mark Serono
EMR 200125-002

Figure 15.4.2.8 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total N4 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments (A, B, C) over time.]

- Subject ID excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 32 tablets of 50 mg of levothyroxine
- Treatment B: 6 tablets of 100 mg of levothyroxine
- Treatment C: 3 tablets of 200 mg of levothyroxine

Source: Listing 15.7.2.5.2

/project24/ep/blinded/e211090_herc/stats/versioncontrol/primary/scripts/program/main/EYL programs/Figures/Figure 15.4.2.9.mso

16DEC2014 09:20

Document No. 0900/09108b00b004 v1.0
CONFIDENTIAL
INFORMATION
Levothyroxine Dosage Form Proportions: \( \text{50 \mu g, 100 \mu g, and 200 \mu g Tablets} \) in Fasted State

Figure 15.4.3.5 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Randon Number:

\[ \text{Treatment: } \bullet \bullet \bullet \text{ Treatment A } \quad \bullet \bullet \bullet \text{ Treatment B } \quad \star \star \star \text{ Treatment C} \]

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 \mu g of Levothyroxine; Treatment B: 6 tablets of 100 \mu g of Levothyroxine; Treatment C: 3 tablets of 200 \mu g of Levothyroxine.

Source: Listing 15.2.5.2

/project247p/alciried/c210998_merged/sates_versioncontrol/primary_scripts/program/main/TL_programs/figures/figure
15.4.2.9.sas
Levothyroxine Dosage Form Properties: Tablets (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

EMR 200125-002

Merek Serono

EMR 200125-002

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for total 74 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for Levothyroxine tablets.]

@Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments. Treatment A: 12 tablets of 50 μg of levothyroxine. Treatment B: 6 tablets of 100 μg of levothyroxine. Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.2.5.2

/project24/wp/blinded/s310998_merc/stats/versioncontrol/primary/scripts/program/main/WL_programs/Figuree/Figuree/15.4.2.9.enm

10DEC2014 00:20

Document No.000063940639497v1.0 CONFIDENTIAL INFORMATION 501658
Levothyroxine Dosage Form Proportions: 50 μg, 100 μg, and 200 μg Tablets in Fasted State

Subject ID/Random Number:

Treatment: ● ● ● Treatment A  ● ● ● Treatment B  ● ● ● Treatment C

Total T4 (μg/dL)

Time Point (h)

0: Subjects excluded from PK Population. Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.3.2

/project24/s/p/blanked/e3i08b_nerc/stats/versioncontrol/primary/scripts/program/main/IFL programs/Figures/Figure 15.4.2.9.was

Document No: D09906eb8058497v1.0  CONFIDENTIAL  502/638
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values) (Safety Population)
Levothyroxine Dosage Form Proportion 
EMR 200125-002

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

8: Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments. Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.2.5.2

/project24/wp/unlighted/031088_narc/stats/versioncontrol/primary/scripts/program/main/CDP programs/Figures/figure15.4.2.9.sas

10DEC2014 00:28

Document No.096980dc8083e6f14.0

CONFIDENTIAL INFORMATION

504518
Levotyroxine Dosage Form Proprietary EMR 200125-002

Figures 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

T₄ (ng/ml)

Treatment A: 2 tablets of 50 μg of levotyroxine; Treatment B: 4 tablets of 100 μg of levotyroxine; Treatment C: 3 tablets of 200 μg of levotyroxine.

Source: Listing 16.2.5.2

/pjekt166/wp/bined/021099_4ecd/stats/versioncontrol/primary/scripts/program/eatn/HIV programs/Figures/figure

Document No. 09006198016910

CONFIDENTIAL INFORMATION

EMR200125-002 Page 505 of 658
Levothyroxine Dosage Form Proportion: 100 µg, 200 µg Tablets in Fasted State

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) [Safety Population]

Subject ID/Random Number:

![Graph showing concentration-time profiles with treatments A, B, and C.]

Treatment:
- Treatment A
- Treatment B
- Treatment C

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levothyroxine.
- Treatment B: 6 tablets of 100 µg of levothyroxine.
- Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.2.5.2

/documents/ep/blinded/e21098_sas/code/primary scripts/main/analysis/FLW program/Figures/Figure 15.4.2.9.sas

16DEC2014 08:23

Document No.0909abca985a9f1v1.0

CONFIDENTIAL INFORMATION
Levothyroxine

Dosage Form Details:
EMR 200125-002

State
EMR200125-002 Page 507 of 658

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values)
(Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Time Point (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment A</td>
<td>0 2 4 6 8 10 12</td>
</tr>
<tr>
<td>Treatment B</td>
<td>0 2 4 6 8 10 12</td>
</tr>
<tr>
<td>Treatment C</td>
<td>0 2 4 6 8 10 12</td>
</tr>
</tbody>
</table>

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.5.2

/project24/ep/blinded/n210898_mrec/stats/versioncontrol/primary/scripts/project/msl/TFL programs/figures/figure
15.4.2.9.msp

Document No:00008898-88586Fv1.0
CONFIDENTIAL INFORMATION

507658
Levothyroxine Dosage Form Proportion: 50 μg, 100 μg, and 200 μg Tablets in Fasted State

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)

(Safety Population)

Subject ID/Random Number:

- **Treatment:**
  - - - Treatment A
  - - - Treatment B
  - - - Treatment C

6: Subjects excluded from PK Population. Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 12 tablets of 50 μg of Levothyroxine.
- Treatment B: 6 tablets of 100 μg of Levothyroxine.
- Treatment C: 3 tablets of 200 μg of Levothyroxine.

Source: Listing 15.2.5.2

/project24/qs/blinded/631058_merc/stats/versioncontrol/scripts/program/min/TFL programs/Figures/Figure 15.4.2.9.sas

10/02/2014 00:20
Levothyroxine
Dosage Form Proportions: EMR 200125-002
Emulsion (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for levothyroxine treatments A, B, and C.]

- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levothyroxine.
- Treatment B: 6 tablets of 100 µg of levothyroxine.
- Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.2.5.2
Levothyroxine Dosage Form Proportion: 50 µg, 100 µg, and 200 µg Tablets in Fasted State

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

- Subjects excluded from PV Population: Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 12 tablets of 10 µg of levothyroxine.
- Treatment B: 6 tablets of 100 µg of levothyroxine.
- Treatment C: 6 tablets of 200 µg of levothyroxine.

Source: Listing 14.2.5.2

/project24/sa/blank/0310099_marc/stats/versioncontrol/primary/scripts/program/ovin/ovl programs/Figures/Figure 15.4.2.9.pdf

10DEC2014 08:20

Document No.1090 bees 08/5/8 v1.0

CONFIDENTIAL

INFORMATION

S101058
Levothyroxine Dosage Form Proportion: \(100\mu g\) Tablets in Fasted State

Subject ID/Random Number: 

Subject excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Treatment A: 12 tablets of 50 \(\mu g\) of levothyroxine; Treatment B: 6 tablets of 100 \(\mu g\) of levothyroxine;
Treatment C: 3 tablets of 200 \(\mu g\) of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/w21898_menc/stats/versioncontrol/primary/scripts/program/main/ITL programs/Figures/Figure 15.6.2.9.sas

10DEC2014 00:30

Document No:96096b6b8045a9f1.0
CONFIDENTIAL
INFORMATION
511658
Liothyronine Dosage Form Proportion:

EMR 200125-002

Figure 15.4.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Time Point (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0  2  4  6  8</td>
</tr>
<tr>
<td>B</td>
<td>1  2  4  6  8</td>
</tr>
<tr>
<td>C</td>
<td>1  2  4  6  8</td>
</tr>
</tbody>
</table>

Notes: Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments.

- Treatment A: 12 tablets of 50 µg of liothyronine
- Treatment B: 6 tablets of 100 µg of liothyronine
- Treatment C: 3 tablets of 200 µg of liothyronine

Source: Listing 16.2.3.2

/project24/exp/klibbean/s210898_mec/stats/versioncontrol/primary/scripts/program/main/TIVL programs/Figures/figure 15.4.9.mso

10DEC2014 09:20

Document No.09908ahesb863be9v1.0 CONFIDENTIAL INFORMATION 512658
Figure S.2: Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for total 74 Values) (Safety Population)

Subject ID/Random Number: 7

- Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 4 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 18.2.5.2

/project344/ep/linocin/v210899/maze/stats/versioncontrol/primary/scripts/program/main/TYL programs/Figures/Figure 15.4.2.9.mls

10/02/2014 00:20
Levothyroxine

Dosage Form Proportions

EMR 200125-002 Page 514 of 658

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

Treatment:  ●  Treatment A  •  Treatment B  ▲  Treatment C

- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levothyroxine, Treatment B: 8 tablets of 100 µg of levothyroxine,
- Treatment C: 3 tablets of 200 µg of levothyroxine.
- Source: listing 16.2.3.2

/project244p/blinded/e216b98_narc/stats/versioncontrol/prnicipals/proc/prninc/TL programs/Figures/Figure
25.4.2.9.sas

10BC02914 00:20

Document No.090096c809369f69v1.0  CONFIDENTIAL

INFORMATION 514658
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values) (Safety Population)

Subject ID/Rand Number: 1

- 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
- 40 60 80 100 120 140 160 180

Total T4 (mu/L)

Time Point (h)

- Treatment: ---- Treatment A  - Treatment B  + Treatment C

6: Subjects excluded from PK Population. Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 10 tablets of 50 μg of levothyroxine; Treatment B: 4 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: Listing 16.2.5.2

/projct24/ep/blinded/x210 contraction/primary/scripts/program/main/TVL programs/Figures/Figure 15.4.2.9.png

10/22/2014 9:02:20

Document No.0906b6e888b09v1.0 CONFIDENTIAL INFORMATION
Levithroxine Dosage Form Proportion: Combinations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Time Point (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0 2 4 6 8 10 12</td>
</tr>
<tr>
<td>B</td>
<td>0 2 4 6 8 10 12</td>
</tr>
<tr>
<td>C</td>
<td>0 2 4 6 8 10 12</td>
</tr>
</tbody>
</table>

8: Subjects excluded from FR Population; Horizontal lines represent the Baseline of the respective treatments. Treatment A: 32 tablets of 50 µg of levithroxine; Treatment B: 6 tablets of 100 µg of levithroxine; Treatment C: 3 tablets of 200 µg of levithroxine.

Source: listing 15.2.5.2

/project24/wp/blinded/010498_merc/stats/versioncontrol/primary/scripts/program/main/YFL programs/Figures/Figure 15.4.2.9.mns

10DEC2014 00:20

Document No:09008ale808589Fv1.0

CONFIDENTIAL
INFORMATION

516658
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1

- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

Source: listing 16.2.5.2

/Project24/ep/clinical/2118697_rec/stats/versioncontrol/primary/scripts/program/main/TEI programs/Figures/Figure 15.4.2.9.png

Document No. 0900b6c8058b0010 CONFIDENTIAL INFORMATION 517658
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject 10/Random Number:

- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levothyroxine.
- Treatment B: 6 tablets of 100 µg of levothyroxine.
- Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 15.2.8.2

/project24/ep0102/210993serc/stats/versioncontrol/primary/scripts/program/main/VEP/programs/Figures/Figure 15.4.2.9.sas

10 DEC 2014 00:26
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values)
(Safety Population)

Subject ID/Random Number:

8: Subjects excluded from PK Populations. Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 22 tablets of 26 µg of levothyroxine.
- Treatment B: 6 tablets of 100 µg of levothyroxine.
- Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Listing 15.2.3.2

/project24/ep/blinded/e210898_marco/stats/versioncontrol/primary/scripts/program/mains/TL program/figures/Figure
15.4.2.9.png

10/26/2014 00:29

Document No.0908abcb0850a97f10 CONFIDENTIAL INFORMATION
Levothyroxine Dosage Form Proprietary
EMR 200125-002 Page 520 of 658

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Randorn Number:

Graph showing concentration-time profiles for three treatments labeled A, B, and C. Horizontal lines represent the baseline of each treatment.

6: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 15.4.2.9
Levothyroxine Dosage Form Proportion: "ions (50 µg, 100 µg, and 200 µg Tablets) in Fasted State"

Figure 15.4.2.5 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

Treatments:
- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Subjects excluded from the population. Horizontal lines represent the Baseline of the respective treatments.

Source: Listing 16.2.5.2

/doc/blinded/c210858hec/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure 15.4.2.5.sse
Figure 25.4.5.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values)
(Safety Population)

Subject ID/Random Number:

Treatment: A C Treatment C

89 Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 22 tablets of 50 μg of levthyroxine; Treatment B: 6 tablets of 100 μg of levthyroxine;
Treatment C: 3 tablets of 200 μg of levthyroxine.
Source: listing 14.2.5.2

/project/244/wa/hlledde221098_merc/stats/versiioncontrol/primary/scripts/program/main/TL_programs/Figures/Figure
15.6.2.9.css

Document No. 090000a0b00c0d0e0f1.0
CONFIDENTIAL
INFORMATION
552658
Levotyroxine Dosage Form Proportion Liases (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values) (Safety Population)

Subject ID/Random Number:

![Graph of Concentration vs Time for Levotyroxine]

- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 32 tablets of 50 μg of levotyroxine.
- Treatment B: 6 tablets of 100 μg of levotyroxine.
- Treatment C: 3 tablets of 200 μg of levotyroxine.

Source: Listing 15.2.3.2

/project/ep/blinded/0210898_masc/stats/versioncontrol/primary/scripts/program/main/TLI Programs/Figures/Figure 15.4.2.9.mes

Document No.090008088968v1.0

CONFIDENTIAL INFORMATION
Levethyroxine Dosage Form Proportions: Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

6 Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 22 tablets of 50 μg of levethyroxine; Treatment B: 6 tablets of 100 μg of levethyroxine.

Treatment C: 3 tablets of 200 μg of levethyroxine.

Source: Listing 16.2.5.2

/project23/gp/blinded/e21999_her/home/rose/contrib/primary/scripts/program/main/44L programs/figures/figure 15.6.2.9.aas

Document No.0990tbe8085ba9v1.0 CONFIDENTIAL INFORMATION 526/64
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) [Safety Population]

Subject ID/Random Number:

Treatment: ●●●● Treatment A  ▲▲▲▲ Treatment B  ▲▲▲▲ Treatment C

Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments. Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.5.2

/project24/bp/blind/1e210298_maco/stats/versioncontrol/prima/scripts/program/main/YUL_programs/Figures/figure 15.4.2.10.aas

10DEC2014 00:28

Document No.0909980890899v1.0

CONFIDENTIAL

INFORMATION

97588
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1

- Treatment: ■■■ Treatment A  ●●● Treatment B  ▲▲▲ Treatment C

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 32 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.1.2.1.2

C:/project24/spl1ed/e3210398.necr/stats/versioncontrol/primary/scripts/program/main/WL/program/Figure/Figure 15.4.2.10.sas
Levothyroxine Dosage Form Propertio: ...EMR200125-002 Page 527 of 658

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population) Subject ID/Rando Number:

Treatment: ●●●● Treatment A ●●●● Treatment B ●●●● Treatment C

- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments. Treatment A: 10 tablets of 30 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.2.5.2

/project24/code/blinded/z110900_merc/scripts/primary/scripts/program/main/ITL programs/Figures/figure 15.4.2.10.sas

10DEC2014 02:28

Document No.0908248500569Fv1.0 CONFIDENTIAL INFORMATION 527658
Levethyroxine Dosage Form Proportion: 150 μg, 100 μg, and 200 μg Tablets in Fasted State

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) [Safety Population] Subject ID/Random Number: 1

Treatment: ●●● Treatment A  ◆◆◆ Treatment B  ▲▲▲ Treatment C

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments. Treatment A: 12 tablets of 50 μg of levethyroxine. Treatment B: 8 tablets of 300 μg of levethyroxine. Treatment C: 3 tablets of 200 μg of levethyroxine. Source: listing 16.2.5.2

/Project24/sp/blinded/210898_erc/zen/stats/versioncontrol/primary/scripts/program/main/7fL Programs/Figures/figure 15.4.2.10.sas
Levothyroxine Dosage Form Proportion - SECTIONS (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total TV Values) (Safety Population)

Subject ID/Random Number:

- Treatment A
- Treatment B
- Treatment C

Subjects excluded from 9% Population: Horizontal lines represent the baseline of the respective treatments.

Treatment A: 10 tablets of 50 μg of levothyroxine.
Treatment B: 6 tablets of 100 μg of levothyroxine.
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.1.5.2

/project24/ep/blinded/s210#90_merc/stats/versioncontrol/primer/scipr/program/main/TWL_programs/Figures/Figure 15.2.10.sas

10DEC2014 00:20

Document No. £9009549.0859v1.0 CONFIDENTIAL INFORMATION 529658
Levothyroxine Dosage Form Proportions: 60 μg, 100 μg, and 200 μg Tablets in Fasted State

Figure 15.4.2.1.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 74 Values; Safety Population)

Subject ID/Random Number:

[Graph showing concentration-time profiles for different treatments, with time points from 0 to 7 hours and concentration levels from 0 to 1000 ng/mL.]

Treatment: ●●● Treatment B ○○○ Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 18.2.5.2
Levothyroxine Dosage Form Proportions: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population) Subject ID/Random Number:

![Graph showing concentration-time profiles of levothyroxine in different treatments.](image)

- **Treatment A**: 12 tablets of 50 μg of levothyroxine
- **Treatment B**: 6 tablets of 100 μg of levothyroxine
- **Treatment C**: 3 tablets of 200 μg of levothyroxine

Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments.

Source: Listing 16.2.5.2

The graph illustrates the concentration-time profiles of levothyroxine in different treatments, with Treatment A receiving 12 tablets of 50 μg, Treatment B receiving 6 tablets of 100 μg, and Treatment C receiving 3 tablets of 200 μg. The concentrations are measured in ng/mL against time points (h).

Document No: 090054b689589f10

CONFIDENTIAL INFORMATION
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

[Graph showing concentration-time profiles for treatment A, B, and C.]

- Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 4 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.5.2

/project124/sp/blinded/0210198_core/stats/versioncontrol/primary/scripts/program/main/YFL programs/Figures/Figure 15.4.2.10.ssm

10DEC2014 05:29
Levothyroxine Dosage Form Proportions: Individual Concentration versus Actual Time in Fasted State (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 13.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale [for Total T4 Values] (Safety Population)

Subject ID/Random Number:

- Treatment: ★★★☆☆☆ Treatment A ★★★★★☆ Treatment B ★★★★★☆ Treatment C
- Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 6 tablets of 200 μg of levothyroxine
- Source: listing 16.2.3.2

/project26/e2/studies/d211698_marc/stats/versioncontrol/primary/scripts/program/main/7FL programs/Figures/Figure 15.4.2.10.sas

Document No: 0990babc8085b4F v1.0

CONFIDENTIAL INFORMATION
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

- Treatment A
- Treatment B
- Treatment C

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine
Treatment B: 6 tablets of 100 μg of levothyroxine
Treatment C: 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.5.2

/project26/ep/blinded/c210998_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Chart

1000x1000 2014 00:20

Document No: 0900abc0823abf0v1.0

CONFIDENTIAL INFORMATION
Levothyroxine
Dosage Form: Propranolol Tablets (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Treatment</th>
<th>Treatment A</th>
<th>Treatment B</th>
<th>Treatment C</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>••</td>
<td>•••</td>
<td>•••</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 2 tablets of 200 µg of levothyroxine.

Source: listing 16.2.5.2

/project24/ep/h114ad/e210898_mero/state/versioncontrol/primary/scripts/program/main/yle programs/figures/figure 15.4.2.10.cas

10DEC2014 00:26

Document No.890009a4805a9v1.0 CONFIDENTIAL INFORMATION 516638
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1

Treatment: ● ● ● Treatment A  ● ● ● ● Treatment B  ▲ ▲ ▲ ▲ Treatment C

- Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective Treatments.
- Treatment A: 12 tablets of 50 μg of Levothyroxine, Treatment B: 6 tablets of 100 μg of Levothyroxine.
- Treatment C: 3 tablets of 200 μg of Levothyroxine.

Source: listing 16.2.5.2

/project24/ap/blinded/c210698_merc/stats/versioncontrol/primary/scripts/program/main/YEL program/Figures/Figure 15.4.2.10.sas

10DEC2014 06:28

Document No.00606aeb803b3a9f700

CONFIDENTIAL INFORMATION 597658
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:  

- Treatment: Treatment A  Treatment B  Treatment C  
- $i$: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.  
- Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.  
- Source: Listing 16.1.5.2

/project24/wp/blinded/c110898_mecr/stats/versioncontrol/primary/scripts/program/mac/DFL_program/Figures/Figure 15.4.2.10.sas
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject 1b Random Number: 1

Treatment: •••• Treatment A  •••• Treatment B  ▲▲▲▲ Treatment C

Subjects excluded from M Population; Horizontal lines represent the baseline of the respective treatments.
Treatment A: 10 tablets of 50 µg of levothyroxine. Treatment B: 6 tablets of 100 µg of levothyroxine.
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 15.2.5.2

/project24/cp/blinded/b210898_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/Figures/Figure 15.4.2.10.sas

10DEC2014 00:20
**Levothyroxine Dosage Form Proportion**

**EMR200125-002 Page 540 of 658**

**Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 74 Values) (Safety Population)**

Subject ID/Random Number:

![Graph showing concentration-time profiles](image)

Treatment: ● ● ● Treatment A

Subjects excluded from PK population. Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.5.2

/project/24/sp/02/imported/e210898_nced/stats/versioncontrol/script/programs_main/FL programs/Figures/figure

15.4.2.10.sas

100012914 06:30

Document No: 0900015085he9/v1.0

CONFIDENTIAL INFORMATION

500355
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total TV Values) (Safety Population) Subject ID/Random Number: ”.

Treatment: ●●● Treatment A  ●●●● Treatment B  ●●●●● Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/wp/h1/ded/e510989_merc/stats/versiocontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

10EB2014 00:20

Document No.0900b6e805b509f+1.0 CONFIDENTIAL INFORMATION 5416658
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 74 Values) (Safety Population)

Subject ID/Random Number:

Treatment:
- Treatment A
- Treatment B
- Treatment C

$: Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 µg of levothyroxine. Treatment B: 6 tablets of 100 µg of levothyroxine.

Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.2.5.2

/project24/sp6/modified/e210688_nesc/stats/variation/primary/scripts/program/main/TRL programs/Figures/Figure 15.4.2.10.sas
Levothyroxine Dosage Form Proportion: 50 μg, 100 μg, and 200 μg Tablets in Fasted State

Figure 15.4.3.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for actual T4 values) (Safety Population) Subject ID/Random Number:

Treatment: ●●● Treatment A  ●●● Treatment B  ●●● Treatment C

0: Subjects excluded from VK population; Horizontal lines represent the baseline of the respective treatments. Treatment A: 22 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.2.3.2

/project24/cm/Blinded/s210898/more/stats/versioncontrol/primary/scripts/program/main/TVL_programs/Figures/Figure 15.4.3.10.sas

Document No.009085085695v1.0 CONFIDENTIAL INFORMATION 545628
Figure 15.6.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (log Total T4 Values) (Safety Population)

Subject ID/Random Number: 1

- Treatment: ○○○○ Treatment A  ●●●● Treatment B  ▲▲▲▲ Treatment C
- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
- Treatment C: 3 tablets of 200 µg of levothyroxine.
- Source: Listing 14.2.5.2

/project24/sp/01ind/c210898_merc/stats/versioncontrol/primary/scripts/program/main/TL programs/Figures/Figure 15.6.2.10.sas
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 3

Treatment: ●●●● Treatment A  •••• Treatment B  ⚫⚫⚫⚫ Treatment C

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments. Treatment A: 10 tablets of 50 µg of levothyroxine; Treatment B: 4 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 14.2.1.2

/project34/ep/blinded/e236696_merc/stats/versioncontrol-primary/scripts/program/main/TPL_process/Figures/Figure 15.4.2.10.sas

10DEC2014 00:23

Document No.0900b66b093b66f1.0

CONFIDENTIAL INFORMATION
Figure 15.4.2.10: Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale

Subject ID/Random Number:

Treatment: ●●● Treatment A  ●●● Treatment B  ▲▲▲ Treatment C

Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine  Treatment B: 4 tablets of 360 μg of levothyroxine
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.2.5.2

/project3d/l INDIRECT/sty/310998/ncrc/stats/primary/scripts/program/main/3FL programs/Figures/Figure 15.4.2.10.sas
Levothyroxine Dosage Form Proportionality EMR 200125-002 Page 547 of 658

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject 15/Random Number:

![Graph showing concentration-time profiles for different treatments.]

- **Treatment A:** 12 tablets of 20 μg of levothyroxine
- **Treatment B:** 8 tablets of 150 μg of levothyroxine
- **Treatment C:** 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.5.2
Levotyroxine Dosage Form Proportion: 
EMR 200125-002 EMR200125-002 Page 548 of 658

Merck Serono Page 24 of 42
ENA 200125-002 Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

![](chart)

Treatment: ○-○-○ Treatment A  ◆◆◆◆◆ Treatment B  △-△-△ Treatment C

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levotyroxine; Treatment B: 6 tablets of 100 μg of levotyroxine; Treatment C: 3 tablets of 200 μg of levotyroxine.

Source: listing 16.2.5.2

/project/24/ep/library/2369907/ncr/s/ncr/primaryscripts/programs/main/47l_programs/figures/figure 15.4.2.10.png

Document No.0900h0e8080ka9r0v1.0 CONFI&DENTIAL INFORMATION 548658
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population) Subject 12/Random Number:

- Treatment: ●●● Treatment A  ▶▶▶ Treatment B  △△△ Treatment C
- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine.
- Treatment C: 3 tablets of 200 µg of levothyroxine.
- Source: listing 16.2.3.2

/project23/ep/blinded/e210898_mace/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/figure 15.4.2.10.sas
**Levothyroxine**

**Dosage Form Proportion:**

**EMR200125-002**

**State:**

**EMR200125-002 Page 550 of 658**

---

**Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) [Safety Population]**

**Subject ID/Random Number:**

---

![Graph showing concentration-time profiles for different treatments](image)

**Treatment:**
- ○-○-○ Treatment A
- ●-●-● Treatment B
- ▲-▲-▲ Treatment C

**Subjects excluded from PK Population:** Horizontal lines represent the baseline of the respective treatments.

- **Treatment A:** 32 tablets of 50 μg of levothyroxine.
- **Treatment B:** 6 tablets of 100 μg of levothyroxine.
- **Treatment C:** 3 tablets of 200 μg of levothyroxine.

**Source:** Listing 15.2.5.2

/project4/mp/slipseed/c210808_merc/stats/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.msx

---

Document No:09009a8b0805a8f8v1.0

CONFIDENTIAL

INFORMATION

550658
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Treatment A</th>
<th>Treatment B</th>
<th>Treatment C</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>●●●●</td>
<td>●●●●</td>
<td>●●●●●</td>
</tr>
<tr>
<td>2</td>
<td>●●●●●</td>
<td>●●●●●</td>
<td>●●●●●</td>
</tr>
<tr>
<td>4</td>
<td>●●●●●</td>
<td>●●●●●</td>
<td>●●●●●</td>
</tr>
<tr>
<td>6</td>
<td>●●●●●</td>
<td>●●●●●</td>
<td>●●●●●</td>
</tr>
<tr>
<td>8</td>
<td>●●●●●</td>
<td>●●●●●</td>
<td>●●●●●</td>
</tr>
</tbody>
</table>

Subjects excluded from M Population. Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.2.5.2

/project/24/ep/blinded/a210899_nerc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sso

Document No:9099abc085b9Fv1.0

CONFIDENTIAL
INFORMATION
55/658
Levothyroxine Dosage Form Proportion EMR 200125-002

EMR 200125-002 Page 552 of 658

Figure 15.4.2.3.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ○ Treatment A • Treatment B ● Treatment C

Subjects excluded from PK Population. Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.2.5.2
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) Safety Population

Subject ID/Random Number:

Treatment: 
- Treatment A 
- Treatment B 
- Treatment C

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.

Treatment A: 10 tablets of 50 µg of levothyroxine
Treatment B: 6 tablets of 100 µg of levothyroxine
Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 16.2.3.8

/project26/cp/blinded/c210639_merc/state/versioncontrol/primary/scripts/program/asis/Wrl programs/Figures/Figure 15.4.2.10.wel

DECE2014 03:29
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Dual-Logarithmic Scale (for Total T4 Values) (Safety Population)

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.

Source: Listing 15.2.5.2
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: Treatment A  Treatment B  Treatment C

Subjects excluded from FN Population: Horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine.
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.4.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/MFL programs/Figures/figure
15.4.2.10.png
Figure 15.6.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment:
- Treatment A
- Treatment B
- Treatment C

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine.
Treatment B: 8 tablets of 100 μg of levothyroxine.
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.5.2

/project/.../stats/primary/.../p_15_6_2_10.eas

13032014 08:22
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Non-Logarithmic Scale (for Total 74 Values) (Safety Population)

Subject ID/Random Number:

Treatment: 
- - - - Treatment A 
- - - - Treatment B 
- - - - Treatment C

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.4.2

/project24580/modified/x210898_merge/stats/versioncontrol/primary/scripts/program/main/SSL programs/Figures/Figure 15.4.2.10.sas

10DEC2014 00:20
Levothyroxine Dosage Form Proportion: Tablets (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ✦✦✦ Treatment B

Subjects excluded from PK Population; horizontal lines represent the baseline of the respective treatments.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 8 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.3.5.2

/project24/ep/blinded/e210898_mer/0/stats/versioncontrol/primary/scripts/program/msio/UTL programs/Figures/Figure 15.4.2.10.mss

10DEC2014 00:20

Document No.990000e8508e9Fv1.D

CONFIDENTIAL INFORMATION 559/568
Levothyroxine

Dosage Form Products: 50 mg, 100 mg, and 200 mg Tablets in Fasted State

Mark Serone
EMR 200125-002

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject IV/Random Number:

---

**Figure Legend**

- Treatment: ○○○○ Treatment A
  - Treatment B
  - Treatment C

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 15 tablets of 50 mg of Levothyroxine;
Treatment B: 5 tablets of 100 mg of Levothyroxine;
Treatment C: 3 tablets of 200 mg of Levothyroxine.

Source: Listing 16.1.5.2

/project24/ep/blined/001098_mcr/c/stats/versc/control/primary/scripts/program/main/VFL programs/Figures/FIGURE 15.4.2.10.sas

10DECE2014 00:20

Document No.9009ab8d98e9f9V1.0
CONFIDENTIAL INFORMATION

560658
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●●● Treatment A  ●●●● Treatment B  ●●●● Treatment C

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.

Treatment A: 15 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.5.2

/project24/cp/blinded/co210898_marc/stats/versioncontrol/primary/scripts/program/mois/TLI programs/Figures/figure 15.4.2.10.sas

10DEC2014 00:29
Levotyroxine Dosage Form Proportions (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.3.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population) Subject ID/Random Number:

- Treatment: ●●●● Treatment A  ●●●● Treatment B  ●●●● Treatment C
- Subjects excluded from PK Population; horizontal lines represent the baseline of the respective treatments.
- Treatment A: 12 tablets of 50 µg of levotyroxine; Treatment B: 6 tablets of 100 µg of levotyroxine; Treatment C: 3 tablets of 200 µg of levotyroxine.

Source: Listing 16.2.5.2

/​project​/​ep/​blind​/​w310899_erc/​stats/​versioncontrol/​primary/scripts/​program/​main/​TPL/​programs/​Figures/​Figure 15.4.2.10.sas

1000
100
10
Time Point (h)

Total T4 (ng/mL)
Levothyroxine Dosage Form Proportion: x 100
Percentages (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ● ● ● Treatment A   ○ ○ ○ Treatment B   ▲ ▲ ▲ Treatment C

*Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ap/blinded/s01089b_marz/stats/versioncontrol/primary/scripts/program/main/YYI/program4/Figures/Figure 15.4.2.10.sas

10/28/2014 00:20
Levothyroxine Dosage Form Proportions: 12 tablets of 50 μg, 16 tablets of 100 μg, and 20 tablets of 260 μg Tablets in Fasted State

Figure 15.4.2.10: Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values, Safety Population)

Subject ID/Surname Number:

Treatment:  
- ▲ ▲ ▲ Treatment C
- 6: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
- Treatment A: 12 tablets of 50 μg of levothyroxine,
- Treatment B: 16 tablets of 100 μg of levothyroxine,
- Treatment C: 20 tablets of 260 μg of levothyroxine.

Source: listing 14.1.5.2

/project24/cp/blinded/c210808_marx/stats/versioncontrol/primary/scripts/program/main/TL programs/Figures/Figure 15.4.2.10.xls

10DEC2014 00:29

Document No.09990a0c0808b0f/v1.9
CONFIDENTIAL INFORMATION

564/58
Levothyroxine Dosage Form Proportion: 60 µg (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Subject ID/Random Number:

Figure 15.6.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)

Treatment: ●●● Treatment A  ●●● Treatment B  ●●● Treatment C

Subjects excluded from PK Populations. Horizontal lines represent the baseline of the respective treatments.

Treatment A: 15 tablets of 50 µg of levothyroxine. Treatment B: 4 tablets of 100 µg of levothyroxine.

Source: Listing 16.2.5.2

/project34/oo/blinded/0110899.merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.6.2.10.sas

10DEC1914 09:30

Document No.0900803808356v.1.0 CONFIDENTIAL INFORMATION 565658
Levothyroxine Dosage Form Proportion: Tablets (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population) Subject ID/Random Number:

Treatment: ●-● Treatment A   ○-○ Treatment B   ▲-▲ Treatment C

Notes: Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project74/mk/billmed/e210830_mec/inst/scripts/primary/program/main/TLT programs/Figures/15.4.2.10.sas

1DEC2014 06:20

Document No:90008ahm085ta9v1.0 CONFIDENTIAL INFORMATION 569858
Figure 15.4.2.11 Concentration-Time Profile: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) [Safety Population]

Subject ID/Rando Number:

![Graph showing concentration-time profile with data points for different treatments.

Treatment: ●●● Treatment A  ✦✦✦ Treatment B  ▲▲▲ Treatment C

- Subjects excluded from PK Population
- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

[Path: /project/ep/blinded/00101699_merc/ets/eversioncontrol/primary/scripts/program/main/TWL programs/Figures/Figure 15.4.2.11.ess]
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Randon Number:

- 0: Subjects excluded from PK Population:
  Treatment A: 12 tablets of 50 μg of levothyroxine
  Treatment B: 6 tablets of 100 μg of levothyroxine
  Treatment C: 3 tablets of 300 μg of levothyroxine

20DEC2014 08:20
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) [Safety Population]

Subject ID/Random Number:

Treatment: •••• Treatment A  ▲▲▲▲ Treatment B  ▲▲▲▲ Treatment C

- Subjects excluded from PK Population:
  Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
  Treatment C: 3 tablets of 200 µg of levothyroxine.

/project/35602/blinded/43100698.merc/stats/versioncontrol/primary/scripts/program/main/4FL/programs/Figures/Figure 15.4.2.11.sas

10DE12014 06:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

![Graph](image.png)

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

/project24//ep/blinded/0210688_mers/stats/versioncontrol/primary/scripts/program/main/TPF programs/Figures/Figure 15.4.2.11.sas

LOCAL2014 00:20

Document No.09009abc908b09v1.0 CONFIDENTIAL INFORMATION
Levothyroxine Dosage Form Proportionals
EMR 200125-002 Page 571 of 658

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

Treatment:
- Treatment A: ●●●
- Treatment B: ○○○
- Treatment C: ▲▲▲

Subjexts excluded from PK Population:

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

/project34/op/blinded/010898_mero/stats/versioncontrol/primary/scripts/program/main/7FL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 02:28

Document No.0000b0be0b8b0Fv1.0

CONFIDENTIAL INFORMATION
**Liothyronine Dosage Form Proportion**

EMR 200125-002

**EMR200125-002 Page 572 of 658**

Objective 1.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)

(Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.](image)

- **Treatment A**: 12 tablets of 50 μg of liothyronine
- **Treatment B**: 6 tablets of 100 μg of liothyronine
- **Treatment C**: 3 tablets of 200 μg of liothyronine

Note: Subjects excluded from PK Population:

Treatments A & B: 12 tablets of 50 μg of liothyronine, Treatment C: 6 tablets of 100 μg of liothyronine.
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 73 Values) (Safety Population)

Subject ID/Random Number:

Treatment:  ●●●● Treatment A  ●●●● Treatment B  ▲▲▲▲ Treatment C

#: Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project34/ep/blinded/e310898.mems/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/figure 15.4.2.11.sas

10DEC2014 00:28

Document No.000994688089612v1.0  CONFIDENTIAL INFORMATION  573658
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Rand Number:  

Treatment:  ●●● Treatment A  ••• Treatment B  ▲▲▲ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.

/ep/h2d5/31/0408_04/main/primary/scripts/program/main/FL programs/Figures/Figure 15.4.2.11.sas
Levothyroxine Dosage Form Proportion
EMR 200125-002

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale [for Total 53 Values]
(Safety Population)

Subject ID/Random Number:  **

Treatment:  ●●● Treatment A  ➤Treatment B  ➤➤Treatment C

8 Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

16DEC2014 06:20

Document No.0500b9a8b8b6b6b6v1.0  CONFIDENTIAL  INFORMATION  575658
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 73 Values) (Safety Population)

Subject ID/Random Number: 1

Treatment: ●●● Treatment A  ●●● Treatment B  ▲▲▲ Treatment C

# Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments]
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 73 Values) (Safety Population)

Subject ID/Random Number:

- Treatment: ●●● Treatment A  ●●● Treatment B  ▲▲▲ Treatment C

8: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

/medproject/ep/blinded/021998_marc/storz/versioncontrol/primary/scriptcs/program/main/TTI/program/Figures/Figure 15.4.2.11.sas

Document No.0990b4d0850a9f1v1.0  CONFIDENTIAL  INFORMATION  57857
Figure 15.1.2.1 Concentration-Time Profiles: Individual Concentration Versus Actual Time in Linear Scale (for Total T3 Values)

(Safety Population)

Subject ID/Random Number: **

Time Point (h)

Treatment: ••• Treatment A  ••• Treatment B  ▲▲▲ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levotyroxine; Treatment B: 6 tablets of 100 µg of levotyroxine;
Treatment C: 3 tablets of 300 µg of levotyroxine.
Figure 5.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)

Subject ID/Random Number:  

Treatment:  ● Treatment A  ● Treatment B  ▲ Treatment C

6: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

/project26/ep/blinded/e2110906_paco/stats/versuscontrol-primary/scripts/param/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Document No.09009a9b9c9d9e9f v1.0  CONFIDENTIAL
INFORMATION  580658
Figure 13.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 13 Values)
(Safety Population)

Subject ID/Random Number: 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Time Point (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment A</td>
<td>2 0 6 1 2 4 6 8</td>
</tr>
<tr>
<td>Treatment B</td>
<td>3 6 7 2 4 6 8</td>
</tr>
<tr>
<td>Treatment C</td>
<td>3 6 7 2 4 6 8</td>
</tr>
</tbody>
</table>

Subjects excluded from PK Population:
- Treatment A: 12 tablets of 50 μg of levotyroxine
- Treatment B: 6 tablets of 100 μg of levotyroxine
- Treatment C: 3 tablets of 200 μg of levotyroxine

For more details, refer to /project1244/pd/bilind/0310299_merck/stats/versioncontrol/primary/scripts/program/main/TEC/programs/figures/figure13.4.2.11.msw
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Randon Number: 

8: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

/project/ep/blinded/c210803_merc/stats/versioncontrol/primary/scripts/program/cmc/VT programs/figures/figure 15.4.2.11.sas

10DEC2014 09:26
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

- Treatment: • • • Treatment A
- Treatment: ▲ ▲ ▲ Treatment B
- Treatment: ★ ★ ★ Treatment C

0: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

/Project/54/ap/blinded/s210X39_marc/stats/VersionControl/primary/scripts/program/main/TFL_programs/Figures/Figure 15.4.2.11.sas
Figure 15.4.2.11: Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for treatments A, B, and C.](image)

Treatment:  
- Treatment A: ●●●●
- Treatment B: ■■■■
- Treatment C: ▲▲▲▲

Subjects excluded from analysis:  
- Treatment A: 12 tablets of 50 µg of levothyroxine  
- Treatment B: 6 tablets of 100 µg of levothyroxine  
- Treatment C: 3 tablets of 200 µg of levothyroxine.
Subject ID/Random Number:

Total T3 (ng/mL)

Time Point (h)

Treatment: ●●● Treatment A  ●●● Treatment B  ●●● Treatment C

9 Subjects excluded from PK population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Page 19 of 42
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: 1

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Subjects excluded from PK Population:

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine
Levothyroxine Dosage Form Properties

EMR 200125-002

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)

(Safety Population)

Subject ID/Random Number:

Treatment:

- - - - Treatment A
- - - - - - Treatment B
- - - - - - - - Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

project34/reports/20141023/clinical/primary/scripts/program/main/MFL program/Figures/Figure 15.4.2.11.txt

12/23/2014 00:29

Document No.050016ab8005ab7v1.0 CONFIDENTIAL INFORMATION 587658
Levothyroxine Dosage Form: Proportion: 50 µg, 100 µg, and 200 µg Tablets in Fasted State

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)

Subject ID/Random Number:

8: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine.
Treatment B: 6 tablets of 100 µg of levothyroxine.
Treatment C: 3 tablets of 200 µg of levothyroxine.

/Project24/ep/blinded/210000_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/figure
15.4.2.11.sas
Levothyroxine Dosage Form Proportion: 50 µg, 100 µg, and 200 µg Tablets in Fasted State

Figure 15.1.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Total T3 (mcg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.8</td>
</tr>
<tr>
<td>2</td>
<td>1.6</td>
</tr>
<tr>
<td>4</td>
<td>1.4</td>
</tr>
<tr>
<td>6</td>
<td>1.2</td>
</tr>
<tr>
<td>8</td>
<td>1.0</td>
</tr>
<tr>
<td>10</td>
<td>0.8</td>
</tr>
<tr>
<td>12</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Treatment: • • • • Treatment B

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

/project28/ep/blinded/e210698_marc/stats/versioncontrol/primary/scripts/program/main/FL program/Figures/Figure 15.1.2.11.sas

Document No.09000bde4085be9e910 CONFIDENTIAL INFORMATION 589658
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 73 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments](image-url)
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Treatment:
- - - Treatment A
- - - Treatment B
- - - Treatment C

6 Subjects excluded from PK Populations:
Treatment A: 12 tablets of 50 µg of levothyroxine
Treatment B: 6 tablets of 100 µg of levothyroxine
Treatment C: 3 tablets of 200 µg of levothyroxine.
Figure 15.4.2.11 Concentration-Time Profile: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●● Treatment A      Treatment B       Treatment C

8: Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 8 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

- Subject ID/Random Number: 

- Treatments: 
  - Treatment A: 5 tablets of 50 μg of levothyroxine
  - Treatment B: 6 tablets of 100 μg of levothyroxine
  - Treatment C: 3 tablets of 200 μg of levothyroxine

Subjects excluded from VK population:
- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

/project/ep/clinical/4210846_merc/strait/versioncontrol/primary/scripts/program/main/TVL programs/Figures/Figure 15.4.2.11.sas

10/30/2014 09:20
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale [for Total T3 Values]
(Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Total T3 (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.4</td>
</tr>
<tr>
<td>2</td>
<td>0.8</td>
</tr>
<tr>
<td>4</td>
<td>1.2</td>
</tr>
<tr>
<td>6</td>
<td>1.6</td>
</tr>
<tr>
<td>8</td>
<td>1.8</td>
</tr>
</tbody>
</table>

Treatment: • • • Treatment A  △ △ △ Treatment B  ▲ ▲ ▲ Treatment C

# Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ■■■■ Treatment A  ◢◆◆ ◢◆◆◆ Treatment B  ▲▲▲▲ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine, Treatment B: 6 tablets of 100 μg of levothyroxine, Treatment C: 3 tablets of 200 μg of levothyroxine.